Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.19.1
Consolidated Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Expenses        
Research and development $ 735,844 $ 1,779,609 $ 2,702,213 $ 5,856,197
General and administrative 935,530 1,155,038 2,796,884 2,911,538
Operating expenses 1,671,374 2,934,647 5,499,097 8,767,735
Other loss (income)        
Change in fair value of derivative liability 189 (2,160) (852) (57,839)
Foreign exchange loss 5,819 6,420 16,754 57,406
Interest income (13,397) (5,850) (49,513) (6,241)
Other loss (income) (7,389) (1,590) (33,611) (6,674)
Net and comprehensive loss for the period 1,663,985 2,933,057 5,465,486 8,761,061
Computation of basic loss per share        
Net and comprehensive loss for the period 1,663,985 2,933,057 5,465,486 8,761,061
Series B Preferred stock dividend 23,202 46,626 75,477 142,358
Net and comprehensive loss available to common stockholders $ 1,687,187 $ 2,979,683 $ 5,540,963 $ 8,903,419
Basic and fully diluted loss per share $ 0.67 $ 1.31 $ 2.27 $ 4.41
Basic weighted average number of shares 2,518,452 2,283,245 2,444,065 2,017,977